Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.
ACS medicinal chemistry letters – June 12, 2025
Source: PubMed
Summary
New formulations are revolutionizing how certain psychedelic compounds could treat depression. Injectable and nasal spray versions of DMT and 5-MeO-DMT address prior absorption and metabolism issues. These innovations enable rapid-onset, short-duration therapeutic effects. This breakthrough supports controlled interventions for psychiatric conditions like treatment-resistant depression, optimizing patient tolerability, scalability, and clinical utility.
Abstract
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.